INTRODUCTION AND OBJECTIVES: Intradetrusor onabotuli-numtoxinA (BTX-A) BTX-A injections are an established third-line therapy for the treatment of overactive bladder (OAB). Incomplete bladder emptying requiring clean intermittent catheterization (CIC) is a side effect that limits patient acceptability of BTX-A. There are studies that have evaluated risk factors that predispose to need for CIC, but few have looked at parameters that may confer protection against CIC. Herein we present an initial report of a cohort of men who have undergone prostatectomy and subsequent BTX-A for OAB.
METHODS: A retrospective chart review of patients receiving BTX-A for OAB refractory to antimuscarinics and/or beta 3agonists from 2010 to 2016 was performed. We sought to identify predictors of elevated post-void residual (PVR) leading to CIC in patients not expected to CIC post treatment. A subset of men who had undergone prostatectomy for benign or malignant disease (open or robotic radical prostatectomy (RP), or transurethral procedure (TUR) for BPH were identified. All men received 100 units of onabotulinumtoxinA under local anesthesia by flexible cystoscope. PVR was measured 2 weeks after the procedure. We generally recommend CIC for PVR 200 -349 ml with symptoms or greater than 350mL with or without symptoms. Clinical variables were correlated with PVR/CIC at their subsequent evaluations. Patients with neurogenic DO and those performing CIC prior to BTX-A injection were excluded.
RESULTS: 71 men were identified. Of these, 45 (63.4%) had surgical interventions on their prostate; 23 (32.4 %) had open or robotic RP and 22 (31 %) had a TUR for BPH. The overall rate of CIC was 12.7%. Three (13.6%) men in the TUR group required CIC vs. 6 (23%) who had an intact prostate No men in the RP group required CIC. The median post BTX-A PVR in the RP group was 44 ml when compared to 104 in the TUR group and 197ml in the group with intact prostates. (Table) CONCLUSIONS: The rate of CIC in men receiving BTX-A for OAB in our cohort was 12.7%, somewhat higher than is seen in women. Prior RP appears to have a protective effect against CIC (p¼0.02) and elevation of PVR (p¼0.001). No man required CIC after RP. Prior TUR does not confer protection against CIC (p¼0.5) but may protect against elevation of PVR (p¼.03). A proposed mechanism for better emptying after surgery may be the ability to Valsalva void.
Source of Funding: none

PD39-12 RISK FACTORS RELATED TO POST-PROSTATECTOMY INCONTINENCE AND DEVELOPMENT OF PREDICTIVE NOMOGRAMS
Liang Dong*, Jiayi Li, Yinjie Zhu, Jiahua Pan, Baijun Dong, Wei Xue, Yiran Huang, Shanghai, China, People's Republic of INTRODUCTION AND OBJECTIVES: To investigate and summarize clinical presentations and characteristics of post-prostatectomy incontinence (PPI), and to analyze the relationship between patients' clinicopathological features and PPI incidence, severity and recovery as well.
METHODS: Clinical and pathological data of 364 patients who underwent radical prostatectomy in Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine between February 2013 and February 2015 were prospectively collected, including 7 lifestyle and comorbidity factors (age, BMI, smoking, etc.), 11 preoperative clinical factors (prostate volume, biopsy approaches, preoperative lower urinary symptoms, etc.), surgeon and surgical method, 4 postoperative clinical factors (complications, postoperative PSA, etc.) and 9 pathological factors (pT, pN, Gleason score, etc.). The incidence, severity and recovery of PPI was followed up by phone call and email. Logistic regression analysis Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e749
and Cochran's and Mantel-Haenszel Chi-square test were used to analyze the relationship between all the features and PPI incidence and severity, respectively. A Kaplan-Meier curve was created to clarify recovery of incontinence after prostatectomy. Cox regression analysis was performed in the analysis of influence factors of PPI recovery. Nomograms were formulated based on the results of multivariate analysis and by using the package of rms in R version 2.14.1. RESULTS: All 364 patients had complete data and the medium follow-up time was 17 months. The total immediate incontinence rate was 61.8%. The incontinence rate was 10.4% at the 12th month after the surgery. Risk factors related to PPI incidence included smoking, hypertension, preoperative incontinence, preoperative dysuresia and chief surgeon. Risk factors related to PPI severity included age, preoperative PSA, neutrophil-to-lymphocyte ratio, postoperative urinary stricture and Gleason score. Risk factors related to PPI recovery included age, BMI, diabetes, hernia, biopsy approaches, prostate volume, preoperative incontinence, preoperative dysuresia, preoperative PSA, postoperative urinary stricture and PPI severity. Age, BMI and PPI severity were independent predictor of PPI recovery.
CONCLUSIONS: Incontinence is a very common complication after radical prostatectomy, which adversely affects patients' quality of life. According to the nomograms developed by this study, now it is possible to predict the incidence of PPI and PPI recovery probabilities, which offers a strong evidence to the establishment of personalized prostate cancer management. INTRODUCTION AND OBJECTIVES: Prostate and breast cancer screening in older patients continue to be controversial based on competing and at times contradictory guidelines. Indeed, the appropriate balance between useful, early detection and avoiding over-diagnosis remains elusive for these conditions. There is a gap in knowledge regarding regional factors associated with high rates of screening for either practice in the elderly. In this study, we investigated to what extent these practices are related to each other, and to the intensity of local healthcare practices.
Source of Funding: This study was supported by Award
METHODS: We performed a retrospective cross-sectional study of fee-for-service Medicare beneficiaries in 2012 (100% sample). We calculated rates of prostate-specific antigen (PSA) screening for males by hospital referral region, adjusted for age and race, using a coding algorithm. Rates of screening were compared with regional rates of screening mammography in older women (75+ years old), as well as measures of care aggressiveness (e.g. spending on tests and procedures) and intensity of end-of-life care, which is considered to reflect physician-driven care within regions.
RESULTS: The mean adjusted rate of PSA screening was 22% (range 13-30%). The mean age of screened and unscreened patients was 75.0 and 77.4 years, respectively (p<0.0001). HRR-level PSA screening rates were independent of screening mammography rates in older women (r¼0.058, p¼0.31). PSA screening rates were associated with spending on testing and procedures (r¼0.42, p<0.0001) and various measures of intensity of end-of-life care (r¼0.32, p<0.0001). Screening mammography had low correlation with these intensity measures. CONCLUSIONS: Regional rates of PSA screening rates were independent of screening mammography, thus these practices appear to be driven by different factors. Unlike mammography, PSA screening was associated with local enthusiasm for testing and treatment. This suggests that policies to reduce over-use of PSA in elderly patients may dovetail with efforts to reduce high healthcare utilization generally. Continued recognition of the risk of over-screening in the elderly is needed, and future research should examine the factors motivating these screening practices.
Source of Funding: The Hitchcock Foundation
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RE-EXAMINING PSA DENSITY: DEFINING THE OPTIMAL PSA RANGE AND PATIENTS FOR USING PSA DENSITY TO PREDICT PROSTATE CANCER USING EXTENDED TEMPLATE BIOPSY INTRODUCTION AND OBJECTIVES: Previous guidelines to screen for prostate cancer (PCa) using serum PSA levels led to millions of unnecessary prostate biopsies that revealed no PCa or low-risk PCa that was unlikely to affect survival. PSA density has shown promise as a better marker to indicate prostate biopsy and has been well investigated in the past using sextant or octant biopsies. While most prior studies only showed that PSA density could distinguish between BPH and PCa, we compared the sensitivity and specificity of PSA density versus PSA to detect any and significant PCa across different PSA ranges using the current standard of extended template prostate biopsies.
METHODS: Participants were a prospective cohort of men referred for prostate biopsy using an extended template biopsy scheme to evaluate PCa at 26 sites throughout the US. We analyzed the area under the receiver operating characteristic curve to assess the predictive accuracy of PSA density versus PSA across three PSA ranges (<4, 4-10, >10 ng/mL) and in men with or without a prior negative biopsy. We assessed the detection of any and significant (Gleason score 7) PCa.
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